These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 805816)

  • 1. Studies of the alternate pathway in chelated serum.
    Forsgren A; Mclean RH; Michael AF; Quie PG
    J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of anticomplementary substances on properdin in normal and C2-deficient sera.
    McLean RH; Townsend K; Michael AF
    Clin Exp Immunol; 1975 Mar; 19(3):435-44. PubMed ID: 1204244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-ethylene glycol tetraacetic acid.
    Des Prez RM; Bryan CS; Hawiger J; Colley DG
    Infect Immun; 1975 Jun; 11(6):1235-43. PubMed ID: 806523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activating property of the protein-rich endotoxin (OEP) of Pseudomonas aeruginosa. I. Activation of both the classical and the alternative pathways of guinea pig complement.
    Inada K
    Jpn J Exp Med; 1980 Feb; 50(1):13-21. PubMed ID: 6770130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consumption of complement in chelated and nonchelated guinea pig serum after challenge with some viral and nonviral interferon inducers.
    Rathová V; Kocisková D; Krizanová O; Borecký L
    Acta Virol; 1976 Feb; 20(1):86-8. PubMed ID: 7949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.
    Adam C; Williams DG; Peters DK
    Clin Exp Immunol; 1975 Nov; 22(2):240-8. PubMed ID: 813932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C3 shunt activation in human serum chelated with EGTA.
    Fine DP; Marney SR; Colley DG; Sergent JS; Des Prez RM
    J Immunol; 1972 Oct; 109(4):807-9. PubMed ID: 4627510
    [No Abstract]   [Full Text] [Related]  

  • 8. The requirement of specific antibody for the killing of E. coli by the alternate complement pathway in bovine serum.
    Hill AW; Shears AL; Hibbitt KG
    Immunology; 1978 Jan; 34(1):131-6. PubMed ID: 75177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ethyleneglycoltetraacetic acid and its magnesium salt as reagents for studying alternative complement pathway function.
    Fine DP
    Infect Immun; 1977 Apr; 16(1):124-8. PubMed ID: 406201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotherapy of primary rat mammary carcinoma: inhibition by ethylenedinitrilotetraacetic acid but not by [ethylenebis(oxyethylenenitrilo)]tetraacetic acid.
    Nakanishi K; Zbar B; Borsos T; Glenn G
    Cancer Res; 1986 Aug; 46(8):3886-90. PubMed ID: 3089581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the alternative pathway of complement in childhood acute lymphoblastic leukemia.
    Kalwinsky DK; Urmson JR; Stitzel AE; Spitzer RE
    J Lab Clin Med; 1976 Nov; 88(5):745-56. PubMed ID: 1068203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternate complement pathway induction of aggregation and release of 5-hydroxytryptamine and adenosine diphosphate by rabbit platelets.
    Marney SR; Colley DG; Des Prez RM
    J Immunol; 1975 Feb; 114(2 Pt 1):696-703. PubMed ID: 804512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the alternative pathway of complement by Acanthamoeba culbertsoni.
    Ferrante A; Rowan-Kelly B
    Clin Exp Immunol; 1983 Nov; 54(2):477-85. PubMed ID: 6418422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative measurement of properdin in normal human serum by electroimmunoassay and single radial immunodiffusion.
    Persson K; Kindmark CO; Pensky J; Naff G
    Clin Exp Immunol; 1977 Jul; 29(1):84-8. PubMed ID: 408067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative complement pathway activity in sera from patients with sickle cell disease.
    Koethe SM; Casper JT; Rodey GE
    Clin Exp Immunol; 1976 Jan; 23(1):56-60. PubMed ID: 816581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A properdin system intermediate formed by zymosan and serum at 0 degrees C.
    Yukiyama Y; Lew FT; Waks HS; Osler AG
    J Immunol; 1976 Jan; 116(1):188-93. PubMed ID: 812914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schistosoma mansoni: the role of the complement C3-activating system in the cercaricidal action of normal serum.
    Machado AJ; Gazzinelli G; Pellegrino J; Dias de Silva W
    Exp Parasitol; 1975 Aug; 38(1):20-9. PubMed ID: 807484
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
    Ruley EJ; Forristal J; Davis NC; Andres C; West CD
    J Clin Invest; 1973 Apr; 52(4):896-904. PubMed ID: 4693654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of murine complement by cobra venom factor in the presence of EDTA.
    Goldman JN; Bangalore S; Goldman MB
    J Immunol; 1979 Nov; 123(5):2421-7. PubMed ID: 114590
    [No Abstract]   [Full Text] [Related]  

  • 20. Complete absence of the third component of complement in man.
    Ballow M; Shira JE; Harden L; Yang SY; Day NK
    J Clin Invest; 1975 Sep; 56(3):703-10. PubMed ID: 1159084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.